RT Journal Article
SR Electronic
T1 Timely referral for advanced therapy in Parkinson’s disease. Development of a screening tool
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.02.10.21251496
DO 10.1101/2021.02.10.21251496
A1 Moes, Harmen R.
A1 ten Kate, Jolien
A1 Portman, Axel T.
A1 van Harten, Barbera
A1 van Kesteren, Mirjam E.
A1 Mondria, Tjeerd
A1 Lunter, Gerton
A1 Buskens, Erik
A1 van Laar, Teus
YR 2021
UL http://medrxiv.org/content/early/2021/02/12/2021.02.10.21251496.abstract
AB Objectives To develop a screening tool for timely referral for advanced therapy (AT) in patients with Parkinson’s disease (PD), and to compare the newly-developed tool with the published 5-2-1 criteria.Design Cross-sectional, diagnostic, observational study and multivariable logistic regression analysis for item selection.Setting 8 hospitals in the Northern part of the Netherlands situated in the catchment area of a specialized movement disorder centre.Participants 259 consecutive PD patients not yet on AT visiting the outpatient clinic of participating hospitals from February 2017 to July 2018.Predictors 24 patient and disease characteristics as assessed by the treating neurologists, and scores on the NMS questionnaire.Outcome Apparent eligibility for referral for AT based on consensus by a panel of 5 experts in the field of AT.Results 17 patients were deemed eligible for referral for AT (point prevalence: 6.6%). Presence of response fluctuations and troublesome dyskinesias were the strongest independent predictors of being eligible for referral. Both variables were included in the final model, as well as levodopa equivalent daily dose. Decision curve analysis showed that the new model outperformed the 5-2-1 criteria. A simple chart was constructed to provide guidance for referral. Discrimination of this simplified scoring system was good (AUC after bootstrapping: 0.97).Conclusion The screening tool may improve efficiency of referral and subsequent treatment with AT in patients with PD. External validation is required prior to application in daily practice.Anyone who wishes to share, reuse, remix, or adapt this material must obtain permission from the corresponding author.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis study was funded by the Dutch Parkinson Patient Association.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Medical Ethical Committee of the University Medical Center Groningen, the Netherlands. Number: METc 2017/123 [waiver for approval].All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesData are available upon reasonable request.